clinical trial · NCT04789174
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study
Excessive Daytime SleepinessObstructive Sleep ApneaImpaired Cognitive FunctionSolriamfetolPlacebo
brief summary
The purpose of study JZP110-405 is to determine whether solriamfetol is effective at improving cognitive function in participants with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA) plus impaired cognitive function.
started
May 17, 2021
primary completion
Sep 19, 2022
completion
Sep 19, 2022
last updated
Jan 26, 2026
official title
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP): a 5-Week Double-blind, Placebo-controlled, Randomized, Crossover, Multicenter Study of Solriamfetol in Improving Cognitive Function in Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Plus Impaired Cognitive Function
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol